# A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma

> **NCT01390948** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 124 (actual)

## Conditions studied

- High Grade Glioma

## Interventions

- **DRUG:** Bevacizumab
- **RADIATION:** Radiotherapy
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT01390948
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-18
- **Primary completion:** 2016-02-05
- **Final completion:** 2020-01-29
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01390948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01390948, "A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01390948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*